Loading
The report of the Chinese trial in which the PD-1 antibody sintilimab produced responses in 75 per cent of people whose NK/T-cell lymphoma had relapsed after asparaginase chemotherapy.
A multicentre, single-arm phase 2 trial (NCT03228836) of sintilimab 200 mg intravenously every three weeks for up to 24 months in relapsed or refractory extranodal NK/T-cell lymphoma after at least one asparaginase-based regimen. The primary endpoint was objective response by the Lugano 2014 criteria. 28 patients were enrolled between 31 August 2017 and 7 February 2018.
Evidence that PD-1 blockade works after asparaginase failure in NK/T-cell lymphoma, a setting with no other standard. Single-arm and small, so it shows activity rather than a comparison with anything else.
Shares Extranodal NK/T-cell lymphoma and the tag lymphoma-evidence-entities.
Shares Extranodal NK/T-cell lymphoma and the tag lymphoma-evidence-entities.
Shares Extranodal NK/T-cell lymphoma and the tag lymphoma-evidence-entities.
Shares Extranodal NK/T-cell lymphoma and the tag lymphoma-evidence-entities.
Shares Sintilimab, Immune checkpoint inhibitors.
Shares Sintilimab, Immune checkpoint inhibitors.
Shares Sintilimab, Immune checkpoint inhibitors.
Shares Sintilimab, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/